Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Ihab Kamel to Liver Neoplasms

This is a "connection" page, showing publications Ihab Kamel has written about Liver Neoplasms.

 
Connection Strength
  
 
 
22.228
  
  1. Afyouni S, Zandieh G, Nia IY, Pawlik TM, Kamel IR. State-of-the-art imaging of hepatocellular carcinoma. J Gastrointest Surg. 2024 Oct; 28(10):1717-1725.
    View in: PubMed
    Score: 0.570
  2. Zandieh G, Yazdaninia I, Afyouni S, Shaghaghi M, Borhani A, Mohseni A, Shaghaghi S, Liddell R, Kamel IR. Spectrum of Imaging Findings and Complications After Hepatic Transarterial Chemoembolization for Liver Tumors. J Comput Assist Tomogr. 2024 Sep-Oct 01; 48(5):701-712.
    View in: PubMed
    Score: 0.558
  3. Mohseni A, Baghdadi A, Madani SP, Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Afyouni S, Zandieh G, Baretti M, Kim AK, Yarchoan M, Kamel IR. Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy: an evaluation of volumetric imaging parameters. Abdom Radiol (NY). 2024 08; 49(8):2595-2605.
    View in: PubMed
    Score: 0.556
  4. Ansari G, Mirza-Aghazadeh-Attari M, Mohseni A, Madani SP, Shahbazian H, Pawlik TM, Kamel IR. Response Assessment of Primary Liver Tumors to Novel Therapies: an Imaging Perspective. J Gastrointest Surg. 2023 10; 27(10):2245-2259.
    View in: PubMed
    Score: 0.530
  5. Shahbazian H, Mirza-Aghazadeh-Attari M, Borhani A, Mohseni A, Madani SP, Ansari G, Pawlik TM, Kamel IR. Multimodality imaging of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Surg Oncol. 2023 Sep; 128(4):519-530.
    View in: PubMed
    Score: 0.530
  6. Madani SP, Mirza-Aghazadeh-Attari M, Mohseni A, Pawlik T, Kamel IR. Diffuse infiltrative hepatocellular carcinoma: Multimodality imaging manifestations. J Surg Oncol. 2023 Mar; 127(3):385-393.
    View in: PubMed
    Score: 0.506
  7. Hazhirkarzar B, Shaghaghi M, Baghdadi A, Ghadimi M, Ghasabeh MA, Wu Q, Tang H, Khoshpouri P, Ameli S, Habibabadi RR, Motaghi M, Meyer CF, Kamel IR. Can Posttransarterial Chemoembolization Volumetric Oil Deposition on Computed Tomography Predict Treatment Response on Magnetic Resonance Imaging in Leiomyosarcoma Metastases to the Liver? J Comput Assist Tomogr. 2022 May-Jun 01; 46(3):327-332.
    View in: PubMed
    Score: 0.485
  8. Baghdadi A, Mirpour S, Ghadimi M, Motaghi M, Hazhirkarzar B, Pawlik TM, Kamel IR. Imaging of Colorectal Liver Metastasis. J Gastrointest Surg. 2022 01; 26(1):245-257.
    View in: PubMed
    Score: 0.470
  9. Hazhirkarzar B, Tang H, Ghadimi M, Baghdadi A, Motaghi M, Wu Q, Shaghaghi M, Kamel I. Predicting early necrosis of colorectal liver metastases using volumetric enhancement on baseline MRI and oil deposition on post-cTACE unenhanced CT. Abdom Radiol (NY). 2021 10; 46(10):4610-4618.
    View in: PubMed
    Score: 0.458
  10. Shaghaghi M, AliyariG Hasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Tang H, Khoshpouri P, Wu Q, Pandey A, Pandey P, Baghdadi A, Kamel IR. Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC. Eur J Radiol. 2020 Dec; 133:109389.
    View in: PubMed
    Score: 0.440
  11. Aliyari Ghasabeh M, Shaghaghi M, Pandey A, Ameli S, Ambale Venkatesh B, Jacob A, Pandey P, Hazhirkarzar B, Luo Y, Rezvani Habibabadi R, Khoshpouri P, Ghadimi M, Kamel IR. Integrating baseline MR imaging biomarkers into BCLC and CLIP improves overall survival prediction of patients with hepatocellular carcinoma (HCC). Eur Radiol. 2021 Mar; 31(3):1630-1641.
    View in: PubMed
    Score: 0.435
  12. Shaghaghi M, Aliyari Ghasabeh M, Ameli S, Ghadimi M, Hazhirkarzar B, Rezvani Habibabadi R, Khoshpouri P, Pandey A, Pandey P, Kamel IR. Post-TACE changes in ADC histogram predict overall and transplant-free survival in patients with well-defined HCC: a retrospective cohort with up to 10 years follow-up. Eur Radiol. 2021 Mar; 31(3):1378-1390.
    View in: PubMed
    Score: 0.435
  13. Ghadimi M, Habibabadi RR, Hazhirkarzar B, Shaghaghi M, Ameli S, Khoshpouri P, Ghasabeh MA, Gurakar A, Pawlik TM, Kamel IR. Advances in Imaging of Diffuse Parenchymal Liver Disease. J Clin Gastroenterol. 2020 09; 54(8):682-695.
    View in: PubMed
    Score: 0.434
  14. Ameli S, Shaghaghi M, Ghasabeh MA, Pandey P, Hazhirkarzar B, Habibabadi RR, Ghadimi M, Khoshpouri P, Pandey A, Kamel IR. Does the change in volumetric functional MR metrics post-TACE predict histopathologic grading of hepatocellular carcinoma? Eur Radiol. 2020 Dec; 30(12):6709-6720.
    View in: PubMed
    Score: 0.430
  15. Ameli S, Shaghaghi M, Aliyari Ghasabeh M, Pandey P, Hazhirkarzar B, Ghadimi M, Rezvani Habibabadi R, Khoshpouri P, Pandey A, Anders RA, Kamel IR. Role of baseline volumetric functional MRI in predicting histopathologic grade and patients' survival in hepatocellular carcinoma. Eur Radiol. 2020 Jul; 30(7):3748-3758.
    View in: PubMed
    Score: 0.420
  16. Fouladi DF, Zarghampour M, Pandey P, Pandey A, Varzaneh FN, Ghasabeh MA, Khoshpouri P, Kamel IR. Baseline 3D-ADC outperforms 2D-ADC in predicting response to treatment in patients with colorectal liver metastases. Eur Radiol. 2020 Jan; 30(1):291-300.
    View in: PubMed
    Score: 0.399
  17. Luo Y, Ameli S, Pandey A, Khoshpouri P, Ghasabeh MA, Pandey P, Li Z, Hu D, Kamel IR. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019 Nov; 29(11):5804-5812.
    View in: PubMed
    Score: 0.397
  18. Luo Y, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Zarghampour M, Khoshpouri P, Ameli S, Li Z, Hu D, Kamel IR. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization. Eur Radiol. 2019 Oct; 29(10):5160-5171.
    View in: PubMed
    Score: 0.392
  19. Zou X, Luo Y, Li Z, Hu Y, Li H, Tang H, Shen Y, Hu D, Kamel IR. Volumetric Apparent Diffusion Coefficient Histogram Analysis in Differentiating Intrahepatic Mass-Forming Cholangiocarcinoma From Hepatocellular Carcinoma. J Magn Reson Imaging. 2019 04; 49(4):975-983.
    View in: PubMed
    Score: 0.379
  20. Shao N, Pandey A, Ghasabeh MA, Khoshpouri P, Pandey P, Varzaneh FN, Zarghampour M, Fouladi D, Pawlik TM, Anders RA, Kamel IR. Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation. Clin Radiol. 2018 11; 73(11):958-965.
    View in: PubMed
    Score: 0.375
  21. Zarghampour M, Fouladi DF, Pandey A, Ghasabeh MA, Pandey P, Varzaneh FN, Khoshpouri P, Shao N, Pan L, Grimm R, Kamel IR. Utility of volumetric contrast-enhanced and diffusion-weighted MRI in differentiating between common primary hypervascular liver tumors. J Magn Reson Imaging. 2018 10; 48(4):1080-1090.
    View in: PubMed
    Score: 0.368
  22. Najmi Varzaneh F, Pandey A, Aliyari Ghasabeh M, Shao N, Khoshpouri P, Pandey P, Zarghampour M, Fouladi D, Liddell R, Anders RA, Kamel IR. Prediction of post-TACE necrosis of hepatocellular carcinoma usingvolumetric enhancement on MRI and volumetric oil deposition on CT, with pathological correlation. Eur Radiol. 2018 Jul; 28(7):3032-3040.
    View in: PubMed
    Score: 0.363
  23. Kaur H, Hindman NM, Al-Refaie WB, Arif-Tiwari H, Cash BD, Chernyak V, Farrell J, Grajo JR, Horowitz JM, McNamara MM, Noto RB, Qayyum A, Lalani T, Kamel IR. ACR Appropriateness Criteria® Suspected Liver Metastases. J Am Coll Radiol. 2017 May; 14(5S):S314-S325.
    View in: PubMed
    Score: 0.345
  24. Chu LC, Pozzessere C, Corona-Villalobos CP, Castaños S, Rastegar N, Halappa V, Bonekamp S, Emurano E, Kamel IR. Evaluation of Hepatocellular Carcinoma Tumor Response After Transcatheter Arterial Chemoembolization Using Gadobenate Dimeglumine-Enhanced Liver Magnetic Resonance. J Comput Assist Tomogr. 2016 Nov/Dec; 40(6):856-862.
    View in: PubMed
    Score: 0.333
  25. Zhu X, Sobhani F, Xu C, Pan L, Ghasebeh MA, Kamel IR. Quantitative volumetric functional MR imaging: an imaging biomarker of early treatment response in hypo-vascular liver metastasis patients after yttrium-90 transarterial radioembolization. Abdom Radiol (NY). 2016 08; 41(8):1495-504.
    View in: PubMed
    Score: 0.327
  26. Xu C, Sobhani F, Murano E, Corona-Villalobos C, Pozzessere C, Rastegar N, Kamel IR. Liver Malignancies Treated With Intra-Arterial Therapy: Assessment of Early Response as Quantified by Volumetric Enhancement Using Gadoxetate Disodium. J Comput Assist Tomogr. 2016 Mar-Apr; 40(2):206-11.
    View in: PubMed
    Score: 0.318
  27. Corona-Villalobos CP, Halappa VG, Bonekamp S, Eng J, Reyes D, Cosgrove D, Rastegar N, Pan L, Pawlik TM, Kamel IR. Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma. Invest Radiol. 2015 Apr; 50(4):283-9.
    View in: PubMed
    Score: 0.298
  28. Corona-Villalobos CP, Halappa VG, Geschwind JF, Bonekamp S, Reyes D, Cosgrove D, Pawlik TM, Kamel IR. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol. 2015 Feb; 25(2):380-90.
    View in: PubMed
    Score: 0.287
  29. Corona-Villalobos CP, Zhang Y, Zhang WD, Kamel IR. Magnetic resonance imaging of the liver after loco-regional and systemic therapy. Magn Reson Imaging Clin N Am. 2014 Aug; 22(3):353-72.
    View in: PubMed
    Score: 0.285
  30. Corona-Villalobos CP, Kamel IR. Functional volumetric MRI in assessing treatment response to intra-arterial therapy of primary and secondary liver tumors. J Comput Assist Tomogr. 2014 Jul-Aug; 38(4):513-7.
    View in: PubMed
    Score: 0.283
  31. Corona-Villalobos CP, Pawlik TM, Kamel IR. Imaging of the patient with a biliary tract or primary liver tumor. Surg Oncol Clin N Am. 2014 Apr; 23(2):189-206.
    View in: PubMed
    Score: 0.272
  32. Bonekamp D, Bonekamp S, Halappa VG, Geschwind JF, Eng J, Corona-Villalobos CP, Pawlik TM, Kamel IR. Interobserver agreement of semi-automated and manual measurements of functional MRI metrics of treatment response in hepatocellular carcinoma. Eur J Radiol. 2014 Mar; 83(3):487-96.
    View in: PubMed
    Score: 0.272
  33. Bonekamp S, Bonekamp D, Geschwind JF, Corona-Villalobos CP, Reyes DK, Pawlik TM, Kamel IR. Response stratification and survival analysis of hepatocellular carcinoma patients treated with intra-arterial therapy using MR imaging-based arterial enhancement fraction. J Magn Reson Imaging. 2014 Nov; 40(5):1103-11.
    View in: PubMed
    Score: 0.271
  34. Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology. 2013 Aug; 268(2):420-30.
    View in: PubMed
    Score: 0.261
  35. Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013 Aug; 268(2):431-9.
    View in: PubMed
    Score: 0.261
  36. Gowdra Halappa V, Corona-Villalobos CP, Bonekamp S, Li Z, Reyes D, Cosgrove D, Pawlik TM, Diaz LA, Bhagat N, Eng J, Geschwind JF, Kamel IR. Neuroendocrine liver metastasis treated by using intraarterial therapy: volumetric functional imaging biomarkers of early tumor response and survival. Radiology. 2013 Feb; 266(2):502-13.
    View in: PubMed
    Score: 0.254
  37. Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF, Kamel IR. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012 Jul; 264(1):285-94.
    View in: PubMed
    Score: 0.245
  38. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data. Radiology. 2011 Sep; 260(3):752-61.
    View in: PubMed
    Score: 0.231
  39. Bonekamp S, Shen J, Salibi N, Lai HC, Geschwind J, Kamel IR. Early response of hepatic malignancies to locoregional therapy-value of diffusion-weighted magnetic resonance imaging and proton magnetic resonance spectroscopy. J Comput Assist Tomogr. 2011 Mar-Apr; 35(2):167-73.
    View in: PubMed
    Score: 0.225
  40. Vossen JA, Buijs M, Geschwind JF, Liapi E, Prieto Ventura V, Lee KH, Bluemke DA, Kamel IR. Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model. J Comput Assist Tomogr. 2009 Jul-Aug; 33(4):626-30.
    View in: PubMed
    Score: 0.200
  41. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009 Feb; 250(2):466-73.
    View in: PubMed
    Score: 0.195
  42. Vossen JA, Buijs M, Liapi E, Eng J, Bluemke DA, Kamel IR. Receiver operating characteristic analysis of diffusion-weighted magnetic resonance imaging in differentiating hepatic hemangioma from other hypervascular liver lesions. J Comput Assist Tomogr. 2008 Sep-Oct; 32(5):750-6.
    View in: PubMed
    Score: 0.189
  43. El-Khouli RH, Geschwind JF, Bluemke DA, Kamel IR. Solitary fibrous tumor of the liver: magnetic resonance imaging evaluation and treatment with transarterial chemoembolization. J Comput Assist Tomogr. 2008 Sep-Oct; 32(5):769-71.
    View in: PubMed
    Score: 0.189
  44. Buijs M, Vossen JA, Hong K, Georgiades CS, Geschwind JF, Kamel IR. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol. 2008 Jul; 191(1):285-9.
    View in: PubMed
    Score: 0.187
  45. Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol. 2008 Jan; 190(1):67-73.
    View in: PubMed
    Score: 0.181
  46. Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007 Jan; 18(1 Pt 1):49-56.
    View in: PubMed
    Score: 0.168
  47. Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar; 17(3):505-12.
    View in: PubMed
    Score: 0.159
  48. Kamel IR, Liapi E, Fishman EK. Multidetector CT of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005 Feb; 19(1):63-89.
    View in: PubMed
    Score: 0.148
  49. Parikh ND, Jones P, Salgia R, Bhan I, Grinspan LT, Jou JH, Zhou K, Jalal P, Roccaro G, Rangnekar AS, Benhammou JN, Pillai A, Mehta N, Wedd J, Yang JD, Kim AK, Duarte-Rojo A, Oloruntoba OO, Tevar A, Au JS, Blain Y, Rao S, Catalano OA, Lewis S, Mendiratta-Lala M, King K, Sachdev L, Lee EW, Bruno J, Kamel I, Tolosa C, Kao K, Badawi T, Przybyszewski EM, Quirk L, Nathani P, Haydel B, Leven E, Wong N, Albertian R, Chen A, Aloor FZ, Mohamed IB, Elkheshen A, Marvil C, Issac G, Clinton JW, Woo SM, Yum J, Rieger E, Hutchison AL, Turner DA, Alsudaney M, Hernandez P, Xu Z, Khalid A, Barrick B, Wang B, Tapper EB, Hao W, Singal AG. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients With Unresectable Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):281-290.e4.
    View in: PubMed
    Score: 0.142
  50. Shahbazian H, Raja K, Sirlin C, Nemzow G, Borhani A, Attari MA, Kamel IR, Chernyak V. Utility of pelvic CT in patients undergoing surveillance for hepatocellular carcinoma: A retrospective multi-institutional study. Abdom Radiol (NY). 2024 11; 49(11):4125-4130.
    View in: PubMed
    Score: 0.141
  51. Aziz H, Underwood PW, Gosse MD, Afyouni S, Kamel I, Pawlik TM. Hepatic adenoma: evolution of a more individualized treatment approach. J Gastrointest Surg. 2024 Jun; 28(6):975-982.
    View in: PubMed
    Score: 0.139
  52. Kamel IR, Fishman EK. Recent advances in CT imaging of liver metastases. Cancer J. 2004 Mar-Apr; 10(2):104-20.
    View in: PubMed
    Score: 0.138
  53. Shahbazian H, Birnbaum J, Burns PJ, Shabanan SH, Kanmaniraja D, Reinus J, Kamel I, Sirlin CB, Chernyak V. Prevalence of different LI-RADS v2018 categories in high-risk patients undergoing CT- or MRI-based screening for hepatocellular carcinoma. Abdom Radiol (NY). 2023 12; 48(12):3696-3702.
    View in: PubMed
    Score: 0.134
  54. Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, Szarf G, Geschwind JF. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003 Sep; 181(3):708-10.
    View in: PubMed
    Score: 0.134
  55. Alden SL, Lim M, Kao C, Shu D, Singal AG, Noonan A, Griffith P, Baretti M, Ho WJ, Kamel I, Yarchoan M, Hsiehchen D. Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma. Cancer Res Commun. 2023 07; 3(7):1312-1317.
    View in: PubMed
    Score: 0.133
  56. Kamel IR, Georgiades C, Fishman EK. Incremental value of advanced image processing of multislice computed tomography data in the evaluation of hypervascular liver lesions. J Comput Assist Tomogr. 2003 Jul-Aug; 27(4):652-6.
    View in: PubMed
    Score: 0.132
  57. Kamel IR, Choti MA, Horton KM, Braga HJ, Birnbaum BA, Fishman EK, Thompson RE, Bluemke DA. Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization. Radiology. 2003 Jun; 227(3):752-7.
    View in: PubMed
    Score: 0.131
  58. Aziz H, Hamad A, Afyouni S, Kamel IR, Pawlik TM. Management of Mucinous Cystic Neoplasms of the Liver. J Gastrointest Surg. 2023 09; 27(9):1963-1970.
    View in: PubMed
    Score: 0.131
  59. Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM, Pawlik TM. Management of Hepatocellular Carcinoma: A Review. JAMA Surg. 2023 04 01; 158(4):410-420.
    View in: PubMed
    Score: 0.130
  60. Kamel IR, Bluemke DA. MR imaging of liver tumors. Radiol Clin North Am. 2003 Jan; 41(1):51-65.
    View in: PubMed
    Score: 0.128
  61. Hamad A, Aziz H, Kamel IR, Diaz DA, Pawlik TM. Yttrium-90 Radioembolization: Current Indications and Outcomes. J Gastrointest Surg. 2023 03; 27(3):604-614.
    View in: PubMed
    Score: 0.127
  62. Aziz H, Brown ZJ, Panid Madani S, Kamel IR, Pawlik TM. Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management. J Am Coll Surg. 2023 02 01; 236(2):399-410.
    View in: PubMed
    Score: 0.126
  63. Kamel IR, Bluemke DA. Imaging evaluation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep; 13(9 Pt 2):S173-84.
    View in: PubMed
    Score: 0.125
  64. Aziz H, Brown ZJ, Baghdadi A, Kamel IR, Pawlik TM. A Comprehensive Review of Hepatic Hemangioma Management. J Gastrointest Surg. 2022 09; 26(9):1998-2007.
    View in: PubMed
    Score: 0.123
  65. Kamel IR, Bluemke DA. Magnetic resonance imaging of the liver: assessing response to treatment. Top Magn Reson Imaging. 2002 Jun; 13(3):191-200.
    View in: PubMed
    Score: 0.123
  66. Aziz H, Brown ZJ, Eskander MF, Aquina CT, Baghdadi A, Kamel IR, Pawlik TM. A Scoping Review of the Classification, Diagnosis, and Management of Hepatic Adenomas. J Gastrointest Surg. 2022 04; 26(4):965-978.
    View in: PubMed
    Score: 0.120
  67. Ghadimi M, Birnbaum J, Kamel IR, Sirlin CB, Chernyak V. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria? Eur Radiol. 2022 May; 32(5):3327-3333.
    View in: PubMed
    Score: 0.118
  68. Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, Charmsaz S, Lin D, Quong D, Wilt B, Kamel IR, Weiss M, Philosophe B, Burkhart R, Burns WR, Shubert C, Ejaz A, He J, Deshpande A, Danilova L, Stein-O'Brien G, Sugar EA, Laheru DA, Anders RA, Fertig EJ, Jaffee EM, Yarchoan M. Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. Nat Cancer. 2021 09; 2(9):891-903.
    View in: PubMed
    Score: 0.116
  69. Jia AY, Popovic A, Mohan AA, Zorzi J, Griffith P, Kim AK, Anders RA, Burkhart RA, Lafaro K, Georgiades C, Azad NS, Liddell RP, Baretti M, Kamel IR, Narang A, Yarchoan M, Meyer J. Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control. 2021 Jan-Dec; 28:10732748211009945.
    View in: PubMed
    Score: 0.111
  70. Chernyak V, Horowitz JM, Kamel IR, Arif-Tiwari H, Bashir MR, Cash BD, Farrell J, Goldstein A, Grajo JR, Gupta S, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR. ACR Appropriateness Criteria® Liver Lesion-Initial Characterization. J Am Coll Radiol. 2020 Nov; 17(11S):S429-S446.
    View in: PubMed
    Score: 0.110
  71. Ho WJ, Sharma G, Zhu Q, Stein-O'Brien G, Durham J, Anders R, Popovic A, Mo G, Kamel I, Weiss M, Jaffee E, Fertig EJ, Yarchoan M. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer. 2020 11; 8(2).
    View in: PubMed
    Score: 0.110
  72. Bashir MR, Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Chernyak V, Goldstein A, Grajo JR, Hindman NM, Kamaya A, McNamara MM, Porter KK, Solnes LB, Srivastava PK, Zaheer A, Carucci LR. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol. 2020 May; 17(5S):S70-S80.
    View in: PubMed
    Score: 0.106
  73. Haj-Mirzaian A, Kadivar A, Kamel IR, Zaheer A. Updates on Imaging of Liver Tumors. Curr Oncol Rep. 2020 04 16; 22(5):46.
    View in: PubMed
    Score: 0.106
  74. Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Hindman NM, Kaur H, McNamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol. 2017 Nov; 14(11S):S391-S405.
    View in: PubMed
    Score: 0.089
  75. Lewis HL, Ghasabeh MA, Khoshpouri P, Kamel IR, Pawlik TM. Functional hepatic imaging as a biomarker of primary and secondary tumor response to loco-regional therapies. Surg Oncol. 2017 Dec; 26(4):411-422.
    View in: PubMed
    Score: 0.088
  76. Margonis GA, Buettner S, Andreatos N, Sasaki K, Pour MZ, Deshwar A, Wang J, Ghasebeh MA, Damaskos C, Rezaee N, Pawlik TM, Wolfgang CL, Kamel IR, Weiss MJ. Preoperative bevacizumab and volumetric recovery after resection of colorectal liver metastases. J Surg Oncol. 2017 Dec; 116(8):1150-1158.
    View in: PubMed
    Score: 0.088
  77. Margonis GA, Sasaki K, Andreatos N, Pour MZ, Shao N, Ghasebeh MA, Buettner S, Antoniou E, Wolfgang CL, Weiss M, Kamel IR, Pawlik TM. Increased kinetic growth rate during late phase liver regeneration impacts the risk of tumor recurrence after colorectal liver metastases resection. HPB (Oxford). 2017 09; 19(9):808-817.
    View in: PubMed
    Score: 0.087
  78. Horowitz JM, Kamel IR, Arif-Tiwari H, Asrani SK, Hindman NM, Kaur H, McNamara MM, Noto RB, Qayyum A, Lalani T. ACR Appropriateness Criteria® Chronic Liver Disease. J Am Coll Radiol. 2017 May; 14(5S):S103-S117.
    View in: PubMed
    Score: 0.086
  79. Pandey P, Lewis H, Pandey A, Schmidt C, Dillhoff M, Kamel IR, Pawlik TM. Updates in hepatic oncology imaging. Surg Oncol. 2017 Jun; 26(2):195-206.
    View in: PubMed
    Score: 0.086
  80. Qu J, Han S, Zhang H, Liu H, Wang Z, Kamel IR, Berthold K, Dominik NM, Zhang S, Dong Y, Jiang L, Liu C, Li H. Improved Detection of Recurrent Hepatocellular Carcinomas in Arterial Phase With CAIPIRINHA-Dixon-TWIST-Volumetric Interpolated Breath-Hold Examination. Invest Radiol. 2016 10; 51(10):602-8.
    View in: PubMed
    Score: 0.083
  81. Fan KY, Wild AT, Halappa VG, Kumar R, Ellsworth S, Ziegler M, Garg T, Rosati LM, Su Z, Hacker-Prietz A, Pawlik TM, Cosgrove DP, Hong KK, Kamel IR, Geschwind JF, Herman JM. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemp Clin Trials. 2016 09; 50:143-9.
    View in: PubMed
    Score: 0.082
  82. Margonis GA, Amini N, Buettner S, Ghasebeh MA, Besharati S, Kim Y, Gani F, Sobhani F, Samaha M, Kamel IR, Pawlik TM. Impact of Perioperative Phosphorus and Glucose Levels on Liver Regeneration and Long-term Outcomes after Major Liver Resection. J Gastrointest Surg. 2016 07; 20(7):1305-16.
    View in: PubMed
    Score: 0.080
  83. Amini N, Margonis GA, Buttner S, Besharati S, Kim Y, Gani F, Sobhani F, Kamel IR, Pawlik TM. Liver regeneration after major liver hepatectomy: Impact of body mass index. Surgery. 2016 07; 160(1):81-91.
    View in: PubMed
    Score: 0.080
  84. Margonis GA, Amini N, Buettner S, Besharati S, Kim Y, Sobhani F, Kamel IR, Pawlik TM. Impact of early postoperative platelet count on volumetric liver gain and perioperative outcomes after major liver resection. Br J Surg. 2016 Jun; 103(7):899-907.
    View in: PubMed
    Score: 0.080
  85. Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: From diagnosis to treatment. Surg Oncol. 2016 Jun; 25(2):74-85.
    View in: PubMed
    Score: 0.080
  86. Samanci C, Sobhani F, Ucbilek E, Rakestraw K, Dagher NN, Kamel IR, Gurakar A. Magnetic Resonance Imaging in Diagnosis and Monitoring of Hepatocellular Carcinoma in Liver Transplantation: A Comprehensive Review. Ann Transplant. 2016 Feb 02; 21:68-76.
    View in: PubMed
    Score: 0.079
  87. Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results. Radiology. 2015 Nov; 277(2):594-603.
    View in: PubMed
    Score: 0.076
  88. Valero V, Amini N, Spolverato G, Weiss MJ, Hirose K, Dagher NN, Wolfgang CL, Cameron AA, Philosophe B, Kamel IR, Pawlik TM. Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2015 Feb; 19(2):272-81.
    View in: PubMed
    Score: 0.073
  89. Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology. 2014 Dec; 273(3):746-58.
    View in: PubMed
    Score: 0.071
  90. Mayo SC, Mavros MN, Nathan H, Cosgrove D, Herman JM, Kamel I, Anders RA, Pawlik TM. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014 Feb; 218(2):196-205.
    View in: PubMed
    Score: 0.068
  91. Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg. 2013 Dec; 17(12):2123-32.
    View in: PubMed
    Score: 0.067
  92. Hyder O, Dodson RM, Weiss M, Cosgrove DP, Herman JM, Geschwind JH, Kamel IR, Pawlik TM. Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. J Gastrointest Surg. 2013 Oct; 17(10):1774-1783.
    View in: PubMed
    Score: 0.067
  93. Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013 Nov; 20(12):3779-86.
    View in: PubMed
    Score: 0.066
  94. Stacy S, Hyder O, Cosgrove D, Herman JM, Kamel I, Geschwind JF, Gurakar A, Anders R, Cameron A, Pawlik TM. Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US. J Gastrointest Surg. 2013 Sep; 17(9):1600-8.
    View in: PubMed
    Score: 0.066
  95. Wood LD, Heaphy CM, Daniel HD, Naini BV, Lassman CR, Arroyo MR, Kamel IR, Cosgrove DP, Boitnott JK, Meeker AK, Torbenson MS. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol. 2013 Dec; 26(12):1586-93.
    View in: PubMed
    Score: 0.065
  96. Kim B, Woreta T, Chen PH, Limketkai B, Singer A, Dagher N, Cameron A, Lin MT, Kamel I, Gurakar A. Donor-transmitted malignancy in a liver transplant recipient: a case report and review of literature. Dig Dis Sci. 2013 May; 58(5):1185-90.
    View in: PubMed
    Score: 0.064
  97. Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013 Mar 01; 119(5):1042-9.
    View in: PubMed
    Score: 0.063
  98. Mayo SC, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. J Am Coll Surg. 2013 Jan; 216(1):123-34.
    View in: PubMed
    Score: 0.063
  99. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, Hong K, Wu Z, Kamel I, Frangakis C. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology. 2012 Oct; 265(1):115-23.
    View in: PubMed
    Score: 0.062
  100. Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013 Apr; 36(2):449-59.
    View in: PubMed
    Score: 0.062
  101. Peng PD, Hyder O, Bloomston M, Marques H, Corona-Villalobos C, Dixon E, Pulitano C, Hirose K, Schulick RD, Barroso E, Aldrighetti L, Choti M, Shen F, Kamel I, Geschwind JF, Pawlik TM. Sequential intra-arterial therapy and portal vein embolization is feasible and safe in patients with advanced hepatic malignancies. HPB (Oxford). 2012 Aug; 14(8):523-31.
    View in: PubMed
    Score: 0.061
  102. Kneuertz PJ, Demirjian A, Firoozmand A, Corona-Villalobos C, Bhagat N, Herman J, Cameron A, Gurakar A, Cosgrove D, Choti MA, Geschwind JF, Kamel IR, Pawlik TM. Diffuse infiltrative hepatocellular carcinoma: assessment of presentation, treatment, and outcomes. Ann Surg Oncol. 2012 Sep; 19(9):2897-907.
    View in: PubMed
    Score: 0.061
  103. Kneuertz PJ, Cosgrove DP, Cameron AM, Kamel IR, Geschwind JF, Herman JM, Pawlik TM. Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation. J Gastrointest Surg. 2012 Apr; 16(4):874-81.
    View in: PubMed
    Score: 0.061
  104. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011 Oct 20; 29(30):3960-7.
    View in: PubMed
    Score: 0.058
  105. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR, Pawlik TM. Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011 Nov; 15(11):2089-97.
    View in: PubMed
    Score: 0.058
  106. Peng PD, van Vledder MG, Tsai S, de Jong MC, Makary M, Ng J, Edil BH, Wolfgang CL, Schulick RD, Choti MA, Kamel I, Pawlik TM. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford). 2011 Jul; 13(7):439-46.
    View in: PubMed
    Score: 0.056
  107. Bonekamp D, Reyes DK, Bonekamp S, Wahlin TA, Geschwind JF, Fishman EK, Kamel IR. Complications of loco-regional therapy in the liver-spectrum of imaging findings by CT and MRI. Emerg Radiol. 2011 Jun; 18(3):249-56.
    View in: PubMed
    Score: 0.056
  108. Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009 Nov-Dec; 15(6):526-32.
    View in: PubMed
    Score: 0.051
  109. Hong K, McBride JD, Georgiades CS, Reyes DK, Herman JM, Kamel IR, Geschwind JF. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009 Mar; 20(3):360-7.
    View in: PubMed
    Score: 0.049
  110. Lee KH, Liapi E, Vossen JA, Buijs M, Ventura VP, Georgiades C, Hong K, Kamel I, Torbenson MS, Geschwind JF. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008 Oct; 19(10):1490-6.
    View in: PubMed
    Score: 0.047
  111. Dorfman JD, Schulick R, Choti MA, Geschwind JF, Kamel I, Torbenson M, Thuluvath PJ. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol. 2007 Feb 07; 13(5):781-4.
    View in: PubMed
    Score: 0.042
  112. Vossen JA, Buijs M, Kamel IR. Assessment of tumor response on MR imaging after locoregional therapy. Tech Vasc Interv Radiol. 2006 Sep; 9(3):125-32.
    View in: PubMed
    Score: 0.041
  113. Kamel IR, Cohade C, Neyman E, Fishman EK, Wahl RL. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdom Imaging. 2004 Nov-Dec; 29(6):663-8.
    View in: PubMed
    Score: 0.035
  114. Borhani A, Luu H, Mohseni A, Xu Z, Shaghaghi M, Tolosa C, Attari MMA, Madani SP, Shahbazian H, Khoshpouri P, Afyouni S, Zandieh G, Kamel IR, Kim AK. Screening for exclusion of high-risk bleeding features of esophageal varices in cirrhosis through CT and MRI. Clin Imaging. 2024 Jun; 110:110168.
    View in: PubMed
    Score: 0.035
  115. Lafaro K, Buettner S, Maqsood H, Wagner D, Bagante F, Spolverato G, Xu L, Kamel I, Pawlik TM. Defining Post Hepatectomy Liver Insufficiency: Where do We stand? J Gastrointest Surg. 2015 Nov; 19(11):2079-92.
    View in: PubMed
    Score: 0.019
  116. Vossen JA, Kamel IR, Buijs M, Liapi E, Georgiades CS, Hong K, Geschwind JF. Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization. J Comput Assist Tomogr. 2008 May-Jun; 32(3):347-52.
    View in: PubMed
    Score: 0.012
  117. Buijs M, Kamel IR, Vossen JA, Georgiades CS, Hong K, Geschwind JF. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol. 2007 Aug; 18(8):957-63.
    View in: PubMed
    Score: 0.011
  118. Kumbasar B, Kamel IR, Tekes A, Eng J, Fishman EK, Wahl RL. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging. 2004 Nov-Dec; 29(6):696-702.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)